Ziad M. El-Zoghby

Ziad M. El-Zoghby

Auto-generated profile, based on publicly available information

Ziad M. El-Zoghby

Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2009 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ZEZ. M. El-Zoghby
Z. M. El-Zoghby
MSM D Stegall
M D Stegall
DLD. J. Lager
D. J. Lager
WKW. K. Kremers
W. K. Kremers
HAH. Amer
H. Amer
MSM. D. Stegall
M. D. Stegall
The causes of kidney allograft loss remain unclear. Herein we investigated these causes in 1317 conventional kidney recipients. The cause of graft loss was determined by reviewing clinical and histologic information the latter available in 98% of cases. During 50.3 ± 32.6 months of follow-up, 330 grafts were lost (25.0%), 138 (10.4%) due to death with function, 39 (2.9%) due to primary nonfunction and 153 (11.6%) due to graft failure censored for death. The latter group was subdivided by cause into: glomerular diseases (n = 56, 36.6%); fibrosis/atrophy (n = 47, 30.7%); medical/surgical conditions (n = 25, 16.3%); acute rejection (n = 18, 11.8%); and unclassifiable (n = 7, 4.6%). Glomerular pathologies leading to failure included recurrent disease (n = 23), transplant glomerulopathy (n = 23) and presumed nonrecurrent disease (n = 10). In cases with fibrosis/atrophy a specific cause(s) was identified in 81% and it was rarely attributable to calcineurin inhibitor (CNI) toxicity alone (n = 1, 0.7%). Contrary to current concepts, most cases of kidney graft loss have an identifiable cause that is not idiopathic fibrosis/atrophy or CNI toxicity. Glomerular pathologies cause the largest proportion of graft loss and alloinmunity remains the most common mechanism leading to failure. This study identifies targets for investigation and intervention that may result in improved kidney transplantation outcomes.

1 January 2015 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
MIMaria V. Irazabal
Maria V. Irazabal
LRLaureano J. Rangel
Laureano J. Rangel
EBEric J. Bergstralh
Eric J. Bergstralh
SOSara L. Osborn
Sara L. Osborn
AHAmber J. Harmon
Amber J. Harmon
VTVicente E. Torres
Vicente E. Torres
The rate of renal disease progression varies widely among patients with autosomal dominant polycystic kidney disease (ADPKD), necessitating optimal patient selection for enrollment into clinical trials. Patients from the Mayo Clinic Translational PKD Center with ADPKD (n=590) with computed tomography/magnetic resonance images and three or more eGFR measurements over ≥6 months were classified radiologically as typical (n=538) or atypical (n=52). Total kidney volume (TKV) was measured using stereology (TKVs) and ellipsoid equation (TKVe). Typical patients were randomly partitioned into development and internal validation sets and subclassified according to height-adjusted TKV (HtTKV) ranges for age (1A-1E, in increasing order). Consortium for Radiologic Imaging Study of PKD (CRISP) participants (n=173) were used for external validation. TKVe correlated strongly with TKVs, without systematic underestimation or overestimation. A longitudinal mixed regression model to predict eGFR decline showed that log2HtTKV and age significantly interacted with time in typical patients, but not in atypical patients. When 1A-1E classifications were used instead of log2HtTKV, eGFR slopes were significantly different among subclasses and, except for 1A, different from those in healthy kidney donors. The equation derived from the development set predicted eGFR in both validation sets. The frequency of ESRD at 10 years increased from subclass 1A (2.4%) to 1E (66.9%) in the Mayo cohort and from 1C (2.2%) to 1E (22.3%) in the younger CRISP cohort. Class and subclass designations were stable. An easily applied classification of ADPKD based on HtTKV and age should optimize patient selection for enrollment into clinical trials and for treatment when one becomes available.

1 October 2016 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
JMJames T. McCarthy
James T. McCarthy
RERokea A. El-Azhary
Rokea A. El-Azhary
MPMichelle T. Patzelt
Michelle T. Patzelt
AWAmy L. Weaver
Amy L. Weaver
RARobert C. Albright
Robert C. Albright
AWAmy W. Williams
Amy W. Williams

1 September 2012 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
ZEZiad M. El-Zoghby
Ziad M. El-Zoghby
JLJohn C. Lieske
John C. Lieske
RFRobert N. Foley
Robert N. Foley
EBEric J. Bergstralh
Eric J. Bergstralh
XLXujian Li
Xujian Li
ARAndrew D. Rule
Andrew D. Rule
Summary: Background and objectives: The contribution of urolithiasis, if any, to the development of ESRD is unclear. Design, setting, participants, & measurements: All stone formers in Olmsted County, Minnesota, first diagnosed between 1984 and 2008 were identified by diagnostic codes with up to four controls matched on age and sex. Charts were reviewed to validate symptomatic stone formers in a random subset. Incident ESRD events were identified by the US Renal Data System. Results: Altogether, 51 stone formers and 75 controls developed ESRD among 6926 stone formers and 24,620 matched controls followed for a mean of 9 years. Stone formers had an increased risk of ESRD after adjusting for diabetes, hypertension, dyslipidemia, gout, and CKD (hazard ratio: 2.09; 95% confidence interval: 1.45–3.01). This increased risk of ESRD remained in the subset of 2457 validated symptomatic stone formers (hazard ratio: 1.95; 95% confidence interval: 1.09–3.49). The attributable risk of ESRD from symptomatic urolithiasis was 5.1% based on a prevalence of 5.4% for stone formers. For stone formers versus controls who developed ESRD, there was an increased likelihood of past hydronephrosis (44% versus 4%), recurrent urinary tract infections (26% versus 4%), acquired single kidney (15% versus 3%), neurogenic bladder (12% versus 1%), and ileal conduit (9% versus 0%), but not diabetes (32% versus 49%) or hypertension (44% versus 52%). Conclusions: Symptomatic stone formers are at increased risk for ESRD independent of several cardiovascular risk factors. Other urological disease is relatively common among stone formers who develop ESRD.

1 November 2008 in Journal of Vascular Surgery
Verified
Journal Article
Closed access
MMM. Hassan Murad
M. Hassan Murad
MEMohamed B. Elamin
Mohamed B. Elamin
ASAnton N. Sidawy
Anton N. Sidawy
GMGerman Malaga
German Malaga
ARAdnan Z. Rizvi
Adnan Z. Rizvi
VMVictor M. Montori
Victor M. Montori

23 November 2009 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
ZEZiad M. El-Zoghby
Ziad M. El-Zoghby
JGJoseph P. Grande
Joseph P. Grande
MFM. G Fraile
M. G Fraile
SNS. M. Norby
S. M. Norby
FFF. C. Fervenza
F. C. Fervenza
FCF. G. Cosio
F. G. Cosio
Membranous nephropathy (MN) recurs posttransplant in 42% of patients. We compared MN recurrence rates in a historical cohort transplanted between 1990 and 1999 and in a current cohort diagnosed by protocol biopsies, we analyzed the progression of the disease and we assessed the effects of anti-CD20 antibodies (Rituximab) on recurrent MN. The incidence of recurrent MN was similar in the historical (53%) and the current cohorts (41%), although in the later the diagnosis was made earlier (median, 4[2–21] months vs. 83[6–149], p = 0.002) and the disease was clinically milder. Twelve out of 14 patients (86%) with recurrent MN in the current cohort had progressive increases in proteinuria. Eight recipients were treated with Rituximab after their proteinuria increased from median, 211 mg/day (64–4898) at diagnosis to 4489 (898–13 855) (p = 0.038). Twelve months post-Rituximab, 75% of patients had either partial (PR) or complete remission (CR). After 24 months 6/7 (86%) had PR/CR and one patient relapsed. Posttreatment biopsies showed resorption of electron dense immune deposits in 6/7 cases and were negative for C3 (4/7) and IgG (3/7). Protocol biopsies allow early diagnosis of subclinical recurrent MN, which is often progressive. Treatment of recurrent MN with Rituximab is promising and should be evaluated in a prospective randomized controlled trial.